Merck Serono commercializes its Concor® family of products containing the active ingredient bisoprolol, a beta1-selective beta-blocker, in more than 90 countries worldwide. The Concor family of products is the backbone of Merck Serono’s cardiovascular franchise which is marketed along with a range of locally commercialized products.

Bisoprolol is characterized by its high beta1-selectivity (helping to avoid undesirable ß2 mediated side-effects on lung function, peripheral circulation, serum lipids and carbohydrate metabolism) and by its robust pharmacokinetics which enable once-daily administration and high bioavailability.

Bisoprolol is approved and marketed in the following indications and trade names:

• Hypertension:
  • For first-line treatment of hypertension - Concor®, Concore® Emcor®, Emconcor®, Détensiel®.
  • In combination with a diuretic (bisoprolol + hydrochlorothiazide - HCTZ) for second-line treatment in selected countries - Concor plus, Emcoretic, Emconcor comp.
  • First-line therapy in a low-dose combination (bisoprolol + HCTZ) - Lodoz, Ziak, Ziac, Biconcor.
• Coronary artery disease: Concor®, Concore®, Emcor®, Emconcor®, Détensiel®
• Chronic heart failure (CHF) : a key component of standard treatment alongside ACE inhibitors - Bisoprolol (Concor, Concor COR, Cardensiel, Cardicor,Congescor, Emconcor CHF, Emconcor COR, Concor IC, Emcor DECO, Emconcor minor.)